New Mexico Educational Retirement Board Sells 24,800 Shares of Illumina, Inc. $ILMN

New Mexico Educational Retirement Board cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 76.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,500 shares of the life sciences company’s stock after selling 24,800 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Illumina were worth $2,053,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ILMN. BlackRock Inc. acquired a new stake in shares of Illumina in the second quarter valued at about $3,374,423,000. WCM Investment Management LLC boosted its position in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA acquired a new position in Illumina during the second quarter valued at approximately $617,981,000. Ninety One UK Ltd grew its stake in Illumina by 37,920.0% in the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock valued at $372,198,000 after purchasing an additional 1,356,397 shares in the last quarter. Finally, Jupiter Topco LLC bought a new position in Illumina in the second quarter valued at approximately $358,652,000. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In related news, Director Keith Meister sold 299,336 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $217.96, for a total value of $65,243,274.56. Following the sale, the director owned 1,409,851 shares in the company, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 1,601,541 shares of company stock worth $354,755,291. 2.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on ILMN. Stifel Nicolaus boosted their price target on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Stephens downgraded Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective for the company. in a report on Friday, October 23rd. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their target price for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Finally, Deutsche Bank lowered shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $244.24.

Key Illumina News

Here’s some of the latest news about ILMN:

• Positive Sentiment: Illumina reported third-quarter 2026 revenue of $1.129 billion and net income of $220 million, and raised its full-year revenue outlook to $4.64 billion–$4.66 billion. The company cited a strong contribution from clinical sequencing consumables, reinforcing demand in a key growth area. Article: How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: Daiwa Securities raised its price target on Illumina to $228 from $196, signaling improved analyst expectations. Article: Daiwa Securities Adjusts Price Target on Illumina to $228 From $196
• Neutral Sentiment: A report noted that Illumina shares returned 76.2% over the past year, reflecting momentum around NovaSeq X uptake, clinical sequencing and multiomics. That strong run may also raise expectations for continued execution. Article: Missed Illumina’s 76% Run? Here Is What Holders Saw

Illumina Trading Down 0.9%

Illumina stock opened at $212.93 on Thursday. The stock has a 50-day simple moving average of $249.39 and a 200 day simple moving average of $179.08. The stock has a market capitalization of $32.20 billion, a P/E ratio of 36.65, a PEG ratio of 2.92 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same quarter in the prior year, the company earned $1.34 earnings per share. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.